G+FLAS Life Sciences

G+FLAS Life Sciences is a technology-intensive global biotech startup that develops genomic editing application products, with 30 full-time researchers, including 10 PhD scientists. The company's mission is "to save lives by producing biologic modifiers for cancer immunotherapy through the use of efficient and more precise gene-editing technologies." G+FLAS Life Sciences is also developing products using CRISPR-PLUS™ technology for applications. For example, developing biosimilars (biologic modifiers) using non-GMO plant genome editing technology. A glycosylation-engineered humanized plant has been developed, in which CRISPR-PLUS™ technology was used to selectively remove glycosylation-related genes from the plant. Based on this genetically modified plant, G+FLAS Life Sciences is developing immunotherapeutic anticancer biologic modifiers such as trastuzumab.